AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
RenovoRx shares surge 11.93% premarket as CEO highlights commercial progress and Phase III trial updates at AGP showcase.
ByAinvest
Thursday, Nov 20, 2025 5:20 am ET1min read
RenovoRx surged 11.93% in premarket trading following the announcement that CEO Shaun Bagai will present at the AGP Emerging AgBiotech/Bio-Solutions Virtual Showcase on November 20. The presentation highlights year-to-date revenue of $900,000 through September 30, 2025, growing adoption of RenovoCath as a standalone device, and advancements in the Phase III TIGeR-PaC trial for intra-arterial gemcitabine in pancreatic cancer. These updates underscore commercial traction and clinical progress, reinforcing investor confidence in the company’s revenue potential and therapeutic pipeline. The event also emphasizes capital-efficient studies and real-world data collection, which could accelerate regulatory validation and broader market adoption of RenovoCath. The positive sentiment aligns with the premarket rally, driven by tangible milestones in commercialization and clinical development.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet